Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of “Moderate Buy” from Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has earned a consensus rating of “Moderate Buy” from the thirteen brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $10.4167.

Several brokerages recently commented on TSHA. UBS Group set a $11.00 target price on Taysha Gene Therapies in a report on Thursday, December 4th. Chardan Capital reaffirmed a “buy” rating and issued a $12.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. Robert W. Baird increased their price objective on shares of Taysha Gene Therapies from $7.00 to $12.00 and gave the stock an “outperform” rating in a research report on Thursday, October 2nd. Citigroup restated an “outperform” rating on shares of Taysha Gene Therapies in a report on Wednesday, November 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $10.00 price target on shares of Taysha Gene Therapies in a research report on Friday, October 17th.

Insider Activity at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 260,047 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $4.51, for a total transaction of $1,172,811.97. Following the transaction, the insider owned 1,006,439 shares in the company, valued at $4,539,039.89. The trade was a 20.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 3.78% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of institutional investors have recently modified their holdings of the company. Invesco Ltd. grew its stake in shares of Taysha Gene Therapies by 83.0% in the 1st quarter. Invesco Ltd. now owns 159,899 shares of the company’s stock worth $222,000 after acquiring an additional 72,544 shares in the last quarter. MetLife Investment Management LLC boosted its holdings in Taysha Gene Therapies by 71.0% during the first quarter. MetLife Investment Management LLC now owns 107,711 shares of the company’s stock worth $150,000 after purchasing an additional 44,721 shares during the last quarter. AQR Capital Management LLC grew its position in Taysha Gene Therapies by 325.6% in the 1st quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock worth $150,000 after purchasing an additional 82,545 shares in the last quarter. Octagon Capital Advisors LP increased its stake in Taysha Gene Therapies by 2.4% in the 1st quarter. Octagon Capital Advisors LP now owns 10,700,000 shares of the company’s stock valued at $14,873,000 after buying an additional 250,000 shares during the last quarter. Finally, Rhumbline Advisers increased its stake in Taysha Gene Therapies by 7.0% in the 1st quarter. Rhumbline Advisers now owns 205,462 shares of the company’s stock valued at $286,000 after buying an additional 13,383 shares during the last quarter. 77.70% of the stock is owned by institutional investors and hedge funds.

Taysha Gene Therapies Stock Performance

NASDAQ TSHA opened at $5.25 on Monday. The company has a market capitalization of $1.44 billion, a price-to-earnings ratio of -15.91 and a beta of 1.02. The company has a quick ratio of 10.48, a current ratio of 10.48 and a debt-to-equity ratio of 0.23. Taysha Gene Therapies has a twelve month low of $1.05 and a twelve month high of $6.02. The stock has a fifty day simple moving average of $4.91 and a 200 day simple moving average of $3.79.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its earnings results on Tuesday, November 4th. The company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative return on equity of 67.26% and a negative net margin of 1,144.97%. Sell-side analysts expect that Taysha Gene Therapies will post -0.35 EPS for the current year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.